Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Astrazeneca Plc LSE:AZN London Ordinary Share GB0009895292 ORD SHS $0.25
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  166.00 1.57% 10,752.00 10,748.00 10,750.00 10,844.00 10,666.00 10,682.00 2,587,961 16:35:19
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 27,668.9 -196.0 5.9 1,620.0 166,561

Astrazeneca Share Discussion Threads

Showing 5576 to 5593 of 5875 messages
Chat Pages: 235  234  233  232  231  230  229  228  227  226  225  224  Older
DateSubjectAuthorDiscuss
21/2/2022
16:25
2.5 billion jabs ... hundreds of millions saved. Never mind the huge leaps forward across their range of products. A fantastic company .. every second day there's an announcement. Could double from here imo. Well done the scientists ...
mapocho
21/2/2022
16:11
Very satisfactory.
patientcapital
21/2/2022
11:10
This morning's statement is a big deal
wish i wasnt in rbs
20/2/2022
02:19
mapocho, millions of dead around the world due to the jab, will disagree with you

The usa reporting system vaers.......reports 25,000 dead from the jab

In small print vaers says only 1-10% of deaths reported

FOI reply public health scotland ..8th Dec - 28th May 2021 5522 died in scotland within 28 days of a jab

https://dailyexpose.uk/2021/07/18/5522-people-have-died-within-28-days-of-having-a-covid-19-vaccine-in-scotland-according-to-public-health-scotland/

jimarilo
20/2/2022
02:12
Military Arrests SCJ Sonia Sotomayor
By Michael Baxter -February 18

U.S. Marines on Wednesday arrested Supreme Court Justice Sonia Sotomayor following a 3-month investigation into whether she had accepted cash payoffs for rulings favoring mask and vaccination mandates and knowingly made false statements to amplify Covid fear.

The truth is coming .....

https://realrawnews.com/2022/02/military-arrests-scj-sonia-sotomayor/

jimarilo
16/2/2022
19:58
Back in for more today.
woodyjmw
15/2/2022
16:16
Fantastic company here. Saving millions of lives also.
mapocho
15/2/2022
13:57
Keep going RR.
woodyjmw
15/2/2022
11:53
Well done the scientists.
philanderer
15/2/2022
11:53
As well as another good news story;

ASTRAZENECA : JP Morgan remains its Buy rating
02/15/2022 | 11:05am GMT
JP Morgan is positive on the stock with a Buy rating. The target price continues to be set at GBX 10000.

beckers2008
14/2/2022
15:08
Just take a look at the manipulated vaers numbers and the yellow card reporting system

They are both corrupt, but still show thousands of deaths

The real numbers are in the millions .......including kids and pregnant women

jimarilo
14/2/2022
15:05
Household name for murder !!!
jimarilo
14/2/2022
15:04
AZ are pure murdering scum .......manufacturers of poison ........FACT !!
jimarilo
14/2/2022
10:34
HL View/Comment published on the 10th Feb:

AstraZeneca's coronavirus vaccine has made it a household name worldwide, but the group's promise to sell the vaccine at cost ''during the pandemic'' means it's padded revenue but not profits. 2022 will pave a new road for the group's coronavirus medicines business--with vaccine sales waning and a monoclonal antibody treatment making up a larger proportion of sales, we can expect to see some of those dollars start to funnel through to the bottom line.

This in addition to the potential growth runway coming from the Alexion acquisition have given management the confidence to increase shareholder returns, but remember dividends are variable and not guaranteed.

Alexion brings rare disease treatments into the AZN fold, a fundamentally attractive area of the pharmaceutical market. The combination of Astra's massive distribution network and Alexion's specialized drugs should bring about a powerful windfall in the coming years.

Rare diseases are, by definition, uncommon. In the past spending millions, perhaps billions, on researching a drug to treat a few tens of thousands of patients worldwide didn't make financial sense. Instead attention focused on treatments for common diseases, like asthma, with patients stretching into the tens of millions. As a result, only around 5% of designated rare diseases have approved treatments.

More recently that attitude has shifted. While major diseases may have large markets, they also attract lots of competition. That means individual drugs companies can end up with a relatively small slice of a large pie. Competition in rare diseases is far lower - a drug company which develops a treatment for a previously unaddressed illness will likely end up serving the entire market and can probably attach a hefty price tag to boot. It's also unlikely a competitor will develop a more effective alternative, since competition is so much lower. Increased interest in the sector means the global rare disease market is forecasted to grow by a low double-digit percentage.

Breaking into this market didn't come cheap, though. The acquisition more than doubled Astra's debt pile and sent free cash into the red. But this pales in comparison to the potential growth the combination offers. This is particularly true when it comes to emerging markets. Alexion's been primarily selling to the US and Europe, but under Astra's wing a greater proportion can be sold further afield. This is of course dependent on regulatory approval, but as AZN already has footholds in these markets it should make the process more efficient.

Cash flow will be of utmost importance moving forward--debt now stands at more than 3 times underlying cash profits. With interest rates on the rise, we'd like to see that come down to more manageable levels. Shareholder returns are also marching higher, so the demands on cash are not insignificant. Any missteps in the Alexion integration, and the group will either have to saddle itself with more debt or trim the dividend.

Overall we think Astra is pretty well placed. It's too early to say whether the Alexion deal will deliver on its potential, but a strong core business and the promise of rising coronavirus treatment profits are encouraging. If all goes to plan the future is bright.

beckers2008
13/2/2022
13:56
Beckers, thanks for the IC article.
philanderer
13/2/2022
10:03
Neither approved by Swissmedic who concluded that their data did not support the benefit/risk equation. AZN then (I believe) withdrew their submission.
alphorn
13/2/2022
08:59
Apologies if this is slightly off topic but did the AZN covid vaccine ever get approved for use in the US by the FDA? If not, was it due to AZN not really going for it ?TIA
paulboz
11/2/2022
13:03
No problem RR, nice to share good news on AZ, which they thoroughly deserve.

'17 times UBS’s EPS estimates for 2022' that's good value especially with the increase in dividend, gives the market confidence. Well done AZ!

beckers2008
Chat Pages: 235  234  233  232  231  230  229  228  227  226  225  224  Older
Your Recent History
LSE
AZN
Astrazenec..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20230208 20:12:56